Bharat Biotech

300k doses of intranasal Covid vaccine sent to hospitals: Krishna Ella

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru. iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26. The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. On whether Bharat Biotech is looking at exporting the vaccine, he said some countries and international agencies are approaching the company for the intra-nasal vaccine. iNCOVACC is also the wor

iNCOVACC: All you need to know about world's first intranasal Covid vaccine

The vaccine been approved for use as a primary as well as a heterologous (mix-and-match) booster dose in India

Bharat Biotech rolls out India's first intra-nasal Covid vaccine iNCOVACC

Priced at Rs 800/dose for private players, Rs 325 for bulk procurement by govts

Health Minister Mandaviya launches Bharat Biotech's nasal Covid-19 vaccine

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The world's first made-in-India intranasal vaccine was launched at Mandaviya's residence here. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued by Bharat Biotech earlier, 'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said. Clinical trials were conducted to evaluate iNCOVACC as a primary dose

Bharat Biotech starts voluntary recall of rabies vaccine after batch theft

Company had tested the batch and released it, but part of it was stolen, for which cold chain storage integrity was unknown. Decision made to recall the entire batch

First Indian intranasal Covid-19 vaccine to be launched on Jan 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on Jan 26, the company's chairman and managing director Krishna Ella said

Ocugen announces positive data for Bharat Biotech's Covaxin in US trials

The study enrolled 419 US adult participants that were randomized 1:1 to receive two doses of Covaxin or placebo, 28 days apart

Ocugen-Bharat Biotech Covid vaccine meets main goals in US trial: Report

Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States

All you need to know about world's first nasal vaccine for covid

Biological E, Bharat Biotech together sitting on 250 mn Covid vaccine doses

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin. Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government. In March '22, Biological E successfully supplied 10 crore doses to the government. "Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar

Bharat Bio's nasal Covid vaccine to cost Rs 800/dose in private market

Price at Rs 325 per dose for large-volume government procurement, will be on sale late January

Govt approves Bharat Biotech's intranasal Covid-19 vaccine as booster

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening, official sources said. The needle-free vaccine will be available at private hospitals as of now and can be administered as a precaution dose to adults who have been vaccinated with two doses of either Covishield or Covaxin. It is likely to be rolled out in the national Covid vaccination programme soon, they said. The ministry's approval for the intranasal vaccine as a booster comes amid a spurt in Covid cases in China and some other countries. The nasal vaccine -- BBV154 -- had received approval of the Drugs Controller General of India (DCGI) in November for restricted use in an emergency situation for those above 18 years as a heterologous booster dose. "The vaccine branded as iNCOVACC is likely to be introduced on the Co-WIN platform Friday evening onwards. For now, it wi

Covid-19: Bharat Biotech's nasal vaccine gets govt nod as booster shot

The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries

Bharat Biotech urges Centre to include intranasal Covid vaccine in CoWIN

: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international potential partners who have approached the company for manufacturing and distribution of the intranasal vaccine globally. Since iNCOVACC has been approved for Restricted use under emergency situation and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID, the sources told PTI. Currently Bharat Biotech's Covaxin, Serum Institute's Covishield and Covovax, Russian Sputink V and Biological E Ltd's Corbevax are listed in the CoWin portal. The vaccine maker on September 6 announced that its ..

CCI approves Bharat Biotech International-Eastman exports deal

The Competition Commission of India on Monday said it has approved the proposed deal of Bharat Biotech International Ltd for acquiring shares of Eastman Exports Global Clothing Pvt Ltd through a share purchase agreement. The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on it being intimated to the competition watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal. The proposed combination relates to the acquisition of shares of Eastman Exports Global Clothing (EEGC) by Bharat Biotech International Ltd (BBIL) being implemented by way of the share subscription agreement, share purchase agreement. "Given that there are no horizontal overlaps, vertical and/or complementary links between the activities of the BBIL (including its affiliates) and EEGC, the proposed combination is being notified under the green .

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Bharat Biotech gets nasal vaccine nod for use as mix-match booster

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us

Bharat Biotech's Intranasal Covid booster gets DCGI nod for restricted use

As per the vaccine manufacturer, the nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa

Biotech firm Bharat Serums & Vaccines working to reduce import dependence

Firm is develop recombinant products in hormones, eyes acquisitions in South East Asia

PLI schemes should focus on firms making pharma products: Bharat Biotech

Production-linked incentive schemes should also focus on companies providing packaging materials and other services in addition to manufacturers of branded pharmaceutical items to reduce import dependence, according to Bharat Biotech Executive Director Sai Prasad. He also emphasised on shifting the focus towards innovative pharmaceuticals products in order to enhance the margins for industry players. "We already have policies like production-linked incentive (PLI) schemes and research-based schemes and these policies are going to be very helpful for the sector... It is our view that such policies should also focus on companies which provide goods and services to the pharma industry," Prasad told PTI in an interaction. The incentives also need to be given to single-use consumer companies, raw material packaging firms and other service providers in the pharmaceutical supply chain, he added. "If the ecosystem is strong only then the branded companies could be strong," Prasad said. He